GRI Bio, Inc. GRI
Regular-session close
After hours · Nov 17, 5:38 PM ET
- YTD
- -80.49%
- 1 year
- -96.99%
- Market cap
- 2.95M
- EPS (ttm)
- -14.71
- Shares out
- 8.93M
- Forward P/E
- -0.29
- YTD return
- -80.49%
- 1-year return
- -96.99%
- 50-day average
- 0.76778
- 200-day average
- 2.82
- Volume
- 24.45K
- Avg volume
- 219.98K
- Open
- 1.45
- Previous close
- 1.40
- Day's range
- 1.33 – 1.45
- 52-week range
- 1.33 – 64.12
- Analysts
- Strong Buy
- Price target
- 11.50 (+751.7%)
Key statistics
- Enterprise value
- -3.95M
- Price / book
- 0.14
- Free cash flow
- -3.87M
- Total cash
- 6.35M
- Total debt
- 141.00K
- Return on equity
- -189.06%
- Short % of float
- 25.11%
Fundamental scorecard
4 of 25 checks passed on GRI’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 5, 2024 | Ascendiant Capital | main | Buy | Buy |
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gribio.com
News
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
GRI Bio Featured in "Why Now" On-Demand Video Webcast
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks
Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact
Ingram Micro Releases 2025 Sustainable Impact Report
Williams Improves on Key Sustainability Metrics Amid Rising Energy Demand
Your note
Sign in to keep a note on GRI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGRO ALBERT | Officer | Stock Award(Grant) | Apr 20, 2023 | 172,189 |
| CHATURVEDI VIPIN | Officer | Stock Award(Grant) | Apr 20, 2023 | 172,189 |
| HERTZ WALTER MARC | Chief Executive Officer | Stock Award(Grant) | Apr 20, 2023 | 385,510 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.80% | 71,647 | 54.01K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.36% | 32,272 | 24.33K | Sep 29, 2024 |
| HRT Financial LP | 0.16% | 13,965 | 10.53K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.13% | 11,847 | 8.93K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.05% | 4,464 | 3.36K | Sep 29, 2024 |
| Blackrock Inc. | 0.04% | 3,596 | 2.71K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.13% | 11,628 | 8.77K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 203 | 153 | Sep 29, 2024 |
